SELLAS Life Sciences Group, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
SELLAS Life Sciences Group, Inc. (SLS) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.25% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-11
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.25%, a 5.99% increase year-over-year.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.01%, a 5.80% increase year-over-year.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-06-30 was 3.69%, a 28.57% increase year-over-year.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.79%, a 111.73% increase year-over-year.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.25%, a 5.99% increase from fiscal 2024.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.01%, a 6.08% increase from fiscal 2023.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.78%, a 92.86% increase from fiscal 2022.
- SELLAS Life Sciences Group, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.96%, a 86.67% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | 4.25% 10-K · filed 2026-03-19 | ||||||
| 2025-09-30 | 4.25% 10-Q · filed 2025-11-12 | ||||||
| 2025-06-30 | 4.25% 10-Q · filed 2026-08-11 | ||||||
| 2025-03-31 | 4.25% 10-Q · filed 2026-05-12 | ||||||
| 2024-12-31 | 4.01% 10-K · filed 2026-03-19 | ||||||
| 2024-09-30 | 4.01% 10-Q · filed 2025-11-12 | ||||||
| 2024-06-30 | 4.01% 10-Q · filed 2025-08-12 | ||||||
| 2024-03-31 | 4.01% 10-Q · filed 2025-05-13 | ||||||
| 2023-12-31 | 3.78% 10-K · filed 2025-03-20 | ||||||
| 2023-09-30 | 3.78% 10-Q · filed 2024-11-13 | ||||||
| 2023-06-30 | 3.69% 10-Q · filed 2024-08-13 | 3.78% 10-Q · filed 2024-08-13 | |||||
| 2023-03-31 | 3.79% 10-Q · filed 2024-05-14 | ||||||
| 2022-12-31 | 1.96% 10-K · filed 2024-03-28 | ||||||
| 2022-09-30 | 3.00% 10-Q · filed 2023-11-09 | 1.95% 10-Q · filed 2023-11-09 | |||||
| 2022-06-30 | 2.87% 10-Q · filed 2023-08-10 | 1.80% 10-Q · filed 2023-08-10 | |||||
| 2022-03-31 | 1.79% 10-Q · filed 2023-05-11 | ||||||
| 2021-12-31 | 1.05% 10-K · filed 2023-03-16 | ||||||
| 2021-09-30 | 1.01% 10-Q · filed 2022-11-14 | 1.04% 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | 1.12% 10-Q · filed 2022-08-11 | 1.04% 10-Q · filed 2022-08-11 | |||||
| 2021-03-31 | 1.03% 10-Q · filed 2022-05-12 | ||||||
| 2020-12-31 | 0.62% 10-K · filed 2022-03-31 | ||||||
| 2020-09-30 | 0.62% 10-Q · filed 2021-11-12 | ||||||
| 2020-06-30 | 0.53% 10-Q · filed 2021-08-12 | 0.62% 10-Q · filed 2021-08-12 | |||||
| 2020-03-31 | 0.63% 10-Q · filed 2021-05-13 | ||||||
| 2019-12-31 | 2.49% 10-K · filed 2021-03-23 | ||||||
| 2019-09-30 | 2.49% 10-Q · filed 2020-11-13 | ||||||
| 2019-06-30 | 0.00% 10-Q · filed 2020-08-13 | 2.49% 10-Q · filed 2020-08-13 | |||||
| 2019-03-31 | 2.49% 10-Q · filed 2020-05-14 | ||||||
| 2018-12-31 | 2.73% 10-K · filed 2020-03-13 | ||||||
| 2018-09-30 | 2.73% 10-Q · filed 2019-11-14 | ||||||
| 2018-06-30 | 2.86% 10-Q · filed 2018-08-14 | 2.73% 10-Q · filed 2018-08-14 | |||||
| 2018-03-31 | 2.71% 10-Q · filed 2019-05-15 | ||||||
| 2017-09-30 | 0.00% 10-Q · filed 2017-11-09 | 2.73% 10-Q · filed 2019-08-14 | 1.87% 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | 1.58% 10-Q · filed 2017-08-14 | 1.87% 10-Q · filed 2017-08-14 | |||||
| 2017-03-31 | 2.01% 10-Q · filed 2017-05-10 | ||||||
| 2016-12-31 | 1.47% 10-K · filed 2017-03-15 | ||||||
| 2016-09-30 | 1.23% 10-Q · filed 2017-11-09 | 1.25% 10-Q · filed 2017-11-09 | |||||
| 2016-06-30 | 1.41% 10-Q · filed 2017-08-14 | 1.41% 10-Q · filed 2017-08-14 | |||||
| 2016-03-31 | 1.41% 10-Q · filed 2017-05-10 | ||||||
| 2015-12-31 | 1.67% 10-K · filed 2017-03-15 | ||||||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-09 | 1.50% 10-Q · filed 2016-11-09 | |||||
| 2015-06-30 | 1.69% 10-Q · filed 2016-08-09 | 1.50% 10-Q · filed 2016-08-09 | |||||
| 2015-03-31 | 1.41% 10-Q · filed 2016-05-10 | ||||||
| 2014-12-31 | 2.01% 10-K · filed 2017-03-15 | ||||||
| 2014-09-30 | 2.02% 10-Q · filed 2015-11-09 | 2.02% 10-Q · filed 2015-11-09 | |||||
| 2014-06-30 | 0.00% 10-Q · filed 2015-08-06 | 2.02% 10-Q · filed 2014-08-11 | 2.06% 10-Q · filed 2015-08-06 | 2.03% 10-Q · filed 2014-08-11 | |||
| 2014-03-31 | 2.06% 10-Q · filed 2015-05-07 | ||||||
| 2013-12-31 | 1.57% 10-K/A · filed 2016-04-15 | ||||||
| 2013-09-30 | 0.00% 10-Q/A · filed 2013-11-07 | 1.25% 10-Q · filed 2014-11-05 | |||||
| 2013-06-30 | 1.35% 10-Q · filed 2013-08-09 | 1.25% 10-Q · filed 2014-08-11 | |||||
| 2013-03-31 | 1.12% 10-Q · filed 2014-05-06 | ||||||
| 2012-12-31 | 1.05% 8-K · filed 2015-12-04 | ||||||
| 2012-09-30 | 0.85% 10-Q · filed 2012-11-13 | 1.06% 10-Q/A · filed 2013-11-07 | |||||
| 2012-06-30 | 1.12% 10-Q · filed 2012-08-14 | 1.07% 10-Q · filed 2013-08-09 | |||||
| 2012-03-31 | 0.00% 10-Q · filed 2014-11-05 | 1.06% 10-Q · filed 2013-05-09 | |||||
| 2011-09-30 | 1.03% 10-Q · filed 2012-11-13 | 1.59% 10-Q · filed 2012-11-13 | |||||
| 2011-06-30 | 2.53% 10-Q · filed 2012-08-14 | 2.35% 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |